rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
2008-1-28
|
pubmed:abstractText |
To investigate the prognostic value of cyclin E in relation to tumour growth pattern by analysing stage II primary breast cancers from premenopausal women not subjected to any further adjuvant treatment. To analyse the value of cyclin E as a predictor of tamoxifen response, by comparing untreated and treated patients with oestrogen receptor positive tumours.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1472-4146
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
61
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
184-91
|
pubmed:meshHeading |
pubmed-meshheading:17483245-Adult,
pubmed-meshheading:17483245-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17483245-Breast Neoplasms,
pubmed-meshheading:17483245-Chemotherapy, Adjuvant,
pubmed-meshheading:17483245-Cyclin E,
pubmed-meshheading:17483245-Female,
pubmed-meshheading:17483245-Follow-Up Studies,
pubmed-meshheading:17483245-Humans,
pubmed-meshheading:17483245-Lymphatic Metastasis,
pubmed-meshheading:17483245-Middle Aged,
pubmed-meshheading:17483245-Neoplasm Invasiveness,
pubmed-meshheading:17483245-Neoplasm Proteins,
pubmed-meshheading:17483245-Neoplasm Staging,
pubmed-meshheading:17483245-Premenopause,
pubmed-meshheading:17483245-Prognosis,
pubmed-meshheading:17483245-Survival Analysis,
pubmed-meshheading:17483245-Tamoxifen,
pubmed-meshheading:17483245-Treatment Outcome,
pubmed-meshheading:17483245-Tumor Markers, Biological
|
pubmed:year |
2008
|
pubmed:articleTitle |
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
|
pubmed:affiliation |
Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|